Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

AbbVie (NY:ABBV)

215.40 +2.47 (+1.16%)
Official Closing Price Updated: 4:10 PM EDT, Jun 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
98 99 Next >
News headline image
Johnson & Johnson Hopes to Dethrone AbbVie's Biggest Growth Driver. Here's Why Investors Shouldn't Panic ↗
AbbVie's shareholders can sleep easy. 
Via The Motley Fool
News headline image
The S&P 500 Is Expensive, but These 3 Dividend Stocks Still Look Like Bargains ↗
AbbVie, CVS Health, and Verizon Communications are all high-yielding stocks with attractive valuations and robust financials. 
Via The Motley Fool
Topics Stocks
News headline image
3 Dividend Stocks to Buy and Hold Forever ↗
These aren't the most exciting businesses, but they have a lot to offer to long-term investors. 
Via The Motley Fool
News headline image
U.S. Health Care Depth or Global Industry Reach? VHT vs. IXJ ↗
The Vanguard Health Care ETF (VHT) and the iShares Global Healthcare ETF (IXJ) both target health care stocks, but they are tailored to different investor needs. One emphasizes broad, low-cost U.S.... 
Via The Motley Fool
Topics ETFs Intellectual Property
News headline image
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗
AbbVie and Pfizer chart distinct paths in revenue growth, risk, and valuation. Explore how their financials and strategies stack up for investors this year. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Allergy Treatment Market Size, Growth, Forecast By 2035 ↗
The most recent research report on the "Allergy Treatment Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic forecasts, 
Via Talk Markets
Topics Economy
News headline image
Addiction Treatment Market Size, Demand, Growth By 2035 ↗
The most recent research report on the "Addiction Treatment Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic forecasts 
Via Talk Markets
Topics Economy
News headline image
VYM vs. SCHD: Which U.S. Dividend ETF Is a Better Buy? ↗
When choosing dividend ETFs, diversification is a top priority. 
Via The Motley Fool
Topics ETFs
News headline image
2 ETFs That Have Held Up Best During Every Recent Market Pullback ↗
These two exchange-traded funds have soundly beaten the markets during recent downturns. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
Hims & Hers Eyes Global Growth: Will $1.15B Eucalyptus Deal Fuel Its Recovery or Dilute Shareholders? ↗
Hims & Hers is acquiring Australian telehealth platform Eucalyptus as part of its international expansion plan while using $350 million in convertible senior notes. 
Via MarketBeat
Topics Earnings
News headline image
5 High-Yield Stocks and ETFs to Buy and Hold for the Next Decade ↗
Five high-yield names spanning pharmaceuticals, consumer staples, energy, and ETFs offer income investors compelling yields and durable businesses for a ten-year hold. 
Via MarketBeat
Topics ETFs
News headline image
Prediction: These 2 Obesity Drug Stocks Could Double in 2026 ↗
These players are seeing exciting results in clinical trials. 
Via The Motley Fool
News headline image
Chemical Peel Market Size, Industry Share By 2035 ↗
The most recent research report on the "Chemical Peel Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic forecasts, and 
Via Talk Markets
Topics Economy
News headline image
What's the Better Dividend Stock Today: AbbVie or Pfizer? ↗
These healthcare giants have been top dividend stocks for years, and both could be intriguing options to consider right now. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Monster Dividend Stocks to Hold for the Next 10 Years ↗
These stocks are built for the long haul. And they pay great dividends. 
Via The Motley Fool
Topics Energy Intellectual Property
News headline image
The Smartest Growth Stocks to Invest $10,000 in As Investors Rotate Out of Tech ↗
When investors take a risk-off attitude, stocks with attractive, growing dividends are often their safe-haven option. 
Via The Motley Fool
News headline image
Healthcare Stocks Are on Fire -- Don't Miss These Opportunities ↗
The healthcare sector outperformed the rest of the market over the past week. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
News headline image
Opinion: AbbVie Is the Best Dividend King to Buy in an Increasingly Uncertain Market ↗
This big pharma stock checks off a lot of boxes. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
2 Stocks That Are Much Cheaper Than They Look ↗
Looking past stocks because they trade at high trailing earnings multiples can be a costly mistake for investors. 
Via The Motley Fool
News headline image
2 High-Yield Healthcare Stocks to Buy Before They Raise Payouts ↗
One is a well-known pharmaceutical company; the other is the king of the medical device segment. 
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Reasons to Like ABBV and 1 to Stay Skeptical
Over the past six months, AbbVie’s shares (currently trading at $211.15) have posted a disappointing 9.8% loss, well below the S&P 500’s 11.5% gain. This mig... 
Via StockStory
Topics Stocks Supply Chain
News headline image
5 Stocks to Own For the Next 10 Years ↗
All High Quality Names 
Via The Motley Fool
CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research
Via Investor Brand Network
Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
Via Investor Brand Network
InvestorNewsBreaks – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Featured in BioMedWire Editorial on Next-Generation GLP-1 Innovation
Via Investor Brand Network
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Next-Generation CNS Drug Delivery
Via Investor Brand Network
Topics Intellectual Property
News headline image
Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
From BioMedWire
Via GlobeNewswire
News headline image
3 Reasons to Buy AbbVie Stock (ABBV) Like There's No Tomorrow ↗
How does a rising 3.4% dividend and a growing portfolio of drugs sound? 
Via The Motley Fool
Topics Intellectual Property
News headline image
CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research
From BioMedWire
Via GlobeNewswire
News headline image
A Tiny Biotech Just Beat AbbVie's $17 Billion Drug. Should Investors Be Worried? ↗
It's not the news that AbbVie needed, given the challenging year it is having. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
98 99 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.